Your browser doesn't support javascript.
loading
ODAM is a predictor for biomedical recurrence and inhibits the migration and invasion of prostate cancer.
Luo, Yun; Wu, Jie-Ying; Hou, Guo-Liang; Lu, Min-Hua; Shi, Zhi; Di, Jin-Ming.
Afiliación
  • Luo Y; Department of Urology, The 3rd Affiliated Hospital of Sun Yat-Sen University Guangzhou, Guangdong, China.
  • Wu JY; Department of Urology, The 3rd Affiliated Hospital of Sun Yat-Sen University Guangzhou, Guangdong, China.
  • Hou GL; Department of Urology, Foshan First Municipal People's Hospital Foshan 528000, China.
  • Lu MH; Department of Urology, The 3rd Affiliated Hospital of Sun Yat-Sen University Guangzhou, Guangdong, China.
  • Shi Z; Department of Cell Biology & Institute of Biomedicine, National Engineering Research Center of Genetic Medicine, Guangdong Provincial Key Laboratory of Bioengineering Medicine, College of Life Science and Technology, Jinan University Guangzhou, Guangdong, China.
  • Di JM; Department of Urology, The 3rd Affiliated Hospital of Sun Yat-Sen University Guangzhou, Guangdong, China.
Am J Transl Res ; 8(2): 670-9, 2016.
Article en En | MEDLINE | ID: mdl-27158359
Odontogenic ameloblast associated protein (ODAM) is a protein contributed to cell adhesion and has been shown to express in normal prostate tissue, but the expression and significance of ODAM in prostate cancer remain unknown. In this study, we detected the protein expressions of ODAM in 88 prostate cancer tissues with immunohistochemical staining, and found that 53 cases (60.2%) was high expression of ODAM, which was shown in the cytoplasm and paranuclear regions. Furthermore, low expression of ODAM was significantly correlated with lymph node metastasis, preoperative PSA and Gleason score, but not with mean age, follow-up duration, PSM rate and distribution of pathological T stage. Additionally, our results of multivariate analysis showed that low ODAM expression was an independent predictor of biomedical recurrence, while the positive lymph node metastasis, Gleason score, and preoperative PSA were not the independent risks for biomedical recurrence. Overexpression of ODAM did not inhibit the growth of prostate cancer cells PC3, but significant suppressed their invasion and migration with decrease of the protein levels of MMP-2. These results suggest that ODAM is a predictor for biomedical recurrence and inhibits the migration and invasion of prostate cancer.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Am J Transl Res Año: 2016 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Am J Transl Res Año: 2016 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos